Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge Marie Svane

Showing results (1-10 of 312) with videos related to

Pageof 32
Sort By:
Cancer Immunology, Immunotherapy : CII|March 20, 2012
Comment on "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy" by Gustav J. Ullenhag et alInge Marie Svane
Nature Reviews. Clinical Oncology|January 19, 2024
Harnessing neoantigen-specific T cells for precision cancer immunotherapyMarco Donia, Inge Marie Svane
JAMA Oncology|November 7, 2024
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-ReplyMarco Donia, Inge Marie Svane
Ugeskrift for Laeger|November 18, 2015
[Ipilimumab induced colitis]Peter Thielsen, Inge Marie Svane
The Lancet. Oncology|May 2, 2025
Unlocking tumor-infiltrating lymphocyte potential with CRISPR-Cas9Özcan Met, Inge Marie Svane
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNAOzcan Met, Inge Marie Svane
Ugeskrift for Laeger|November 30, 2004
[High dose chemotherapy versus conventional chemotherapy in metastasing breast cancer. An analysis of a systematic Cochrane review]Dorte Lisbet Nielsen, Inge Marie Svane
Cancer Immunology, Immunotherapy : CII|August 8, 2014
Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?Inge Marie Svane, Els M Verdegaal
APMIS. Supplementum|May 13, 2003
Immune selection in murine tumors. Ph.d thesisInge Marie Svane, Anne-Marie Engel
Ugeskrift for Laeger|November 30, 2004
[High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review]Dorte Lisbet Nielsen, Inge Marie Svane
Pageof 32

Showing results (1-10 of 312) with videos related to

Sort By:
Pageof 32
Cancer Immunology, Immunotherapy : CII|March 20, 2012
Comment on "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy" by Gustav J. Ullenhag et alInge Marie Svane
Nature Reviews. Clinical Oncology|January 19, 2024
Harnessing neoantigen-specific T cells for precision cancer immunotherapyMarco Donia, Inge Marie Svane
JAMA Oncology|November 7, 2024
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-ReplyMarco Donia, Inge Marie Svane
Ugeskrift for Laeger|November 18, 2015
[Ipilimumab induced colitis]Peter Thielsen, Inge Marie Svane
The Lancet. Oncology|May 2, 2025
Unlocking tumor-infiltrating lymphocyte potential with CRISPR-Cas9Özcan Met, Inge Marie Svane
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNAOzcan Met, Inge Marie Svane
Ugeskrift for Laeger|November 30, 2004
[High dose chemotherapy versus conventional chemotherapy in metastasing breast cancer. An analysis of a systematic Cochrane review]Dorte Lisbet Nielsen, Inge Marie Svane
Cancer Immunology, Immunotherapy : CII|August 8, 2014
Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?Inge Marie Svane, Els M Verdegaal
APMIS. Supplementum|May 13, 2003
Immune selection in murine tumors. Ph.d thesisInge Marie Svane, Anne-Marie Engel
Ugeskrift for Laeger|November 30, 2004
[High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review]Dorte Lisbet Nielsen, Inge Marie Svane
Pageof 32